1. Home
  2. STRO vs TEI Comparison

STRO vs TEI Comparison

Compare STRO & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STRO
  • TEI
  • Stock Information
  • Founded
  • STRO 2003
  • TEI 1993
  • Country
  • STRO United States
  • TEI United States
  • Employees
  • STRO N/A
  • TEI N/A
  • Industry
  • STRO Biotechnology: Biological Products (No Diagnostic Substances)
  • TEI Finance Companies
  • Sector
  • STRO Health Care
  • TEI Finance
  • Exchange
  • STRO Nasdaq
  • TEI Nasdaq
  • Market Cap
  • STRO 292.6M
  • TEI 264.5M
  • IPO Year
  • STRO 2018
  • TEI N/A
  • Fundamental
  • Price
  • STRO $3.84
  • TEI $5.45
  • Analyst Decision
  • STRO Strong Buy
  • TEI
  • Analyst Count
  • STRO 8
  • TEI 0
  • Target Price
  • STRO $12.13
  • TEI N/A
  • AVG Volume (30 Days)
  • STRO 479.5K
  • TEI 142.4K
  • Earning Date
  • STRO 11-11-2024
  • TEI 01-01-0001
  • Dividend Yield
  • STRO N/A
  • TEI 10.51%
  • EPS Growth
  • STRO N/A
  • TEI N/A
  • EPS
  • STRO N/A
  • TEI N/A
  • Revenue
  • STRO $169,359,000.00
  • TEI N/A
  • Revenue This Year
  • STRO N/A
  • TEI N/A
  • Revenue Next Year
  • STRO N/A
  • TEI N/A
  • P/E Ratio
  • STRO N/A
  • TEI N/A
  • Revenue Growth
  • STRO 197.83
  • TEI N/A
  • 52 Week Low
  • STRO $2.01
  • TEI $4.35
  • 52 Week High
  • STRO $6.13
  • TEI $5.39
  • Technical
  • Relative Strength Index (RSI)
  • STRO 56.69
  • TEI 38.75
  • Support Level
  • STRO $3.22
  • TEI $5.38
  • Resistance Level
  • STRO $3.74
  • TEI $5.68
  • Average True Range (ATR)
  • STRO 0.21
  • TEI 0.09
  • MACD
  • STRO 0.03
  • TEI -0.02
  • Stochastic Oscillator
  • STRO 96.88
  • TEI 18.92

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

About TEI Templeton Emerging Markets Income Fund Inc.

Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.

Share on Social Networks: